15 withdrawn. 15 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Withdrawn 15 |
| Phase 2 | 5 | Withdrawn 5 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers HA115, Placebo - Asthma | Phase 1 | Withdrawn | Conjupro Biotherapeutics, Inc. | 2021-10-01 | 2021-09-08 | |
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2020-09-01 | 2021-05-14 | |
| Anakinra as a Rescue Treatment for Allergic Inflammation Anakinra, Preservative-free 0.9% sodium chloride (Placebo), House dust mite allergen - Asthma, Allergic | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-12-16 | 2022-06-08 | |
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-08-09 | 2021-05-07 | |
| Airway Temperature Segmental Bronchoprovocation with Allergen (SBP-Ag) - Asthma | Phase 1 | Withdrawn | Lu Yuan Lee | 2018-11-08 | 2020-12-09 | |
| A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler Fluticasone Propionate/Salmeterol Xinafoate DISKUS, Placebo to Match DISKUS, Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS - Asthma | Phase 1 | Withdrawn | GlaxoSmithKline | 2014-10-01 | 2015-02-11 | |
| A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003) Low-Dose MK-8351, High-Dose MK-8351, Placebo to MK-8351 - Asthma | Phase 1 | Withdrawn | Merck Sharp & Dohme LLC | 2013-09-01 | 2015-07-16 | |
| Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma AMG 827 or Placebo - Asthma | Phase 1 | Withdrawn | Amgen | 2011-06-01 | 2013-11-25 | |
| A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge Active (PF-03526299), Placebo - Asthma | Phase 1 | Withdrawn | Pfizer | 2011-02-01 | 2011-12-02 | |
| A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval. GSK2190915 100mg, GSK2190915 200mg, moxifloxacin 400mg - Asthma | Phase 1 | Withdrawn | GlaxoSmithKline | 2010-09-01 | 2013-08-21 | |
| Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite Extract dust mite inhalation - Dermatophagoides Farinae Allergy, Asthma | Phase 1 | Withdrawn | University of North Carolina, Chapel Hill | 2009-01-01 | 2017-05-05 | |
| Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus NPPV plus standard of care - Status Asthmaticus | Phase 1 | Withdrawn | Southern Illinois University | 2009-01-01 | 2014-12-19 | |
| Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma QAX576, Placebo - Asthma | Phase 1 / Phase 2 | Withdrawn | Novartis | 2008-01-01 | 2016-03-04 | |
| Evaluation of Lovastatin in Severe Persistent Asthma Lovastatin, Placebo - Severe Persistent Asthma | Phase 1 / Phase 2 | Withdrawn | University of Chicago | 2013-06-21 |
Rhinitis, Allergic (3) · Dermatitis, Atopic (1) · Dust Mite Allergy (1) · Egg Hypersensitivity (1) · Food Hypersensitivity (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Milk Hypersensitivity (1) · Nut Hypersensitivity (1) · Peanut Hypersensitivity (1) · Rhinosinusitis (1) · Status Asthmaticus (1) · Urticaria (1) · Wheat Hypersensitivity (1)
Bronchial Diseases (15) · Immune System Diseases (15) · Respiratory Hypersensitivity (15) · Respiratory Tract Diseases (15) · Hypersensitivity (14) · Hypersensitivity, Immediate (14) · Lung Diseases (14) · Lung Diseases, Obstructive (14) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Rhinitis (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1) · Genetic Diseases, Inborn (1)
Allergens (4) · Antigens, Dermatophagoides (3) · Interleukin 1 Receptor Antagonist Protein (3) · Receptors, Interleukin-6 (2) · 3-(3-tert-butylsulfanyl-1-(4-(6-ethoxypyridin-3-yl)benzyl)-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropionic acid (1) · Anti-Allergic Agents (1) · Dust (1) · Exercise (1) · Fluticasone (1) · Lovastatin (1) · Moxifloxacin (1) · Sensitivity and Specificity (1) · Sodium Chloride (1) · Standard of Care (1) · brodalumab (1)
University of North Carolina, Chapel Hill (4) · GlaxoSmithKline (2) · Amgen (1) · Candid Therapeutics (1) · Conjupro Biotherapeutics, Inc. (1) · Lu Yuan Lee (1) · Merck Sharp & Dohme LLC (1) · Novartis (1) · Pfizer (1) · Southern Illinois University (1) · University of Chicago (1)
United States (3) · Australia (1) · United Kingdom (1)
Michelle Hernandez, MD (3) · Blanca Camoretti-Mercado, Ph.D. (1) · David Peden, MD (1) · Lu Yuan Lee, PhD (1) · Mehdi Khosravi, MD (1) · Michelle Hernandez (1) · Sangita Basnet, MD (1)
R01HL135235 (3), U01AI123832 (1), UL1RR024999 (1)